Access the full text.
Sign up today, get DeepDyve free for 14 days.
Ming-Yii Huang, H. Tsai, Chih‐Hung Lin, Ching-Wen Huang, Cheng‐Jen Ma, Chun-Ming Huang, C. Chai, Jaw-Yuan Wang (2013)Predictive value of ERCC1, ERCC2, and XRCC1 overexpression for stage III colorectal cancer patients receiving FOLFOX‐4 adjuvant chemotherapy
Journal of Surgical Oncology, 108
J. Miura, F. Johnston, James Thomas, B. George, D. Eastwood, S. Tsai, K. Christians, K. Turaga, T. Gamblin (2014)Molecular profiling in gastric cancer: Examining potential targets for chemotherapy
Journal of Surgical Oncology, 110
Y. Kucukzeybek, A. Dirican, Ç. Erten, I. Somalı, A. Can, L. Demir, I. Bayoglu, M. Akyol, Murat Medeni, M. Tarhan (2012)Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Asian Pacific journal of cancer prevention : APJCP, 13 6
A. Popovtzer, M. Sarfaty, D. Limon, Gideon Marshack, Eliyahu Perlow, A. Dvir, L. Soussan-Gutman, S. Stemmer (2015)Metastatic Salivary Gland Tumors: A Single-Center Study Demonstrating the Feasibility and Potential Clinical Benefit of Molecular-Profiling-Guided Therapy
BioMed Research International, 2015
Frances O'Malley, Frances O'Malley, Stephen Chia, Dongsheng Tu, Lois Shepherd, Mark Levine, David Huntsman, Vivien Bramwell, Vivien Bramwell, I Andrulis, I Andrulis, Kathleen Pritchard (2011)Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial
Breast Cancer Research and Treatment, 128
K. Higuchi, S. Tanabe, K. Shimada, H. Hosaka, E. Sasaki, N. Nakayama, Y. Takeda, T. Moriwaki, K. Amagai, T. Sekikawa, T. Sakuyama, T. Kanda, Tohru Sasaki, M. Azuma, F. Takahashi, M. Takeuchi, W. Koizumi (2014)Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial).
European journal of cancer, 50 8
P. Thuss-Patience, A. Kretzschmar, D. Bichev, T. Deist, A. Hinke, K. Breithaupt, Y. Doğan, B. Gebauer, G. Schumacher, P. Reichardt (2011)Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
European journal of cancer, 47 15
P. Bohanes, D. Courvoisier, T. Perneger, P. Morel, O. Huber, A. Roth (2011)Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer.
Swiss medical weekly, 141
D. Hoff, J. Stephenson, P. Rosen, D. Loesch, M. Borad, S. Anthony, G. Jameson, Susan Brown, Nina Cantafio, D. Richards, T. Fitch, E. Wasserman, C. Fernandez, S. Green, W. Sutherland, M. Bittner, A. Alarcon, D. Mallery, R. Penny (2010)Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 33
P. Zucali, M. Ruiz, E. Giovannetti, A. Destro, M. Varella-Garcia, K. Floor, G. Ceresoli, J. Rodriguez, I. Garassino, P. Comoglio, M. Roncalli, A. Santoro, G. Giaccone (2008)Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Annals of oncology : official journal of the European Society for Medical Oncology, 19 9
A. Bilici (2014)Treatment options in patients with metastatic gastric cancer: current status and future perspectives.
World journal of gastroenterology, 20 14
(2013)Class III beta-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer
G. Jameson, E. Petricoin, J. Sachdev, L. Liotta, D. Loesch, S. Anthony, M. Chadha, M. Pierobon, A. Reeder, Monica Fulk, L. Vocila, Nina Cantafio, Bryant Dunetz, N. Robert (2013)A pilot study utilizing molecular profiling to find potential targets and select individualized treatments for patients with metastatic breast cancer.
Journal of Clinical Oncology, 31
J. Hwang, Ji-Yun Hong, Karham Kim, Seung-Hun Kim, Wonyoung Choi, Min-Jee Kim, S. Jung, H. Shim, W. Bae, E. Hwang, Kyung‐Hwa Lee, Jaehyuk Lee, Sang‐Hee Cho, I. Chung (2013)Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer
BMC Cancer, 13
S. Misale, R. Yaeger, S. Hobor, E. Scala, M. Janakiraman, D. Líška, E. Valtorta, R. Schiavo, M. Buscarino, G. Siravegna, K. Bencardino, A. Cercek, Ching-Tung Chen, S. Veronese, C. Zanon, A. Sartore-Bianchi, M. Gambacorta, M. Gallicchio, E. Vakiani, Valentina Boscaro, E. Medico, M. Weiser, S. Siena, F. Nicolantonio, D. Solit, A. Bardelli (2012)Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
R. Ramanathan, M. Barrett, G. Weiss, R. Posner, N. Rajeshkumar, G. Jameson, M. Demeure, A. Hoering, E. Stites, A. Maitra, Monica Fulk, M. Hidalgo, D. Hoff (2012)Abstract LB-221: Phase II study of therapy selected by molecular profiling in patients with previously treated metastatic pancreatic cancer. A study of the stand up to cancer (SU2C) consortium
Cancer Research, 72
Philip Abbosh, S. Sundararajan, S. Millis, A. Hauben, S. Reddy, D. Geynisman, R. Uzzo (2017)Molecular and Genomic Profiling to Identify Actionable Targets in Chromophobe Renal Cell Cancer.
European urology focus, 4 6
K. Gunturu, Y. Woo, N. Beaubier, Helen Remotti, M. Saif (2013)Gastric cancer and trastuzumab: first biologic therapy in gastric cancer
Therapeutic Advances in Medical Oncology, 5
M. Pistelli, M. Scartozzi, A. Bittoni, E. Galizia, R. Berardi, S. Cascinu (2011)Second-line chemotherapy with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) in relapsed or metastatic gastric cancer: lessons from clinical practice.
Tumori, 97 3
P. Johnston, H. Lenz, C. Leichman, K. Danenberg, C. Allegra, P. Danenberg, L. Leichman (1995)Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors.
Cancer research, 55 7
Xi‐De Wang, K. Reeves, F. Luo, Li-an Xu, F. Lee, E. Clark, F. Huang (2007)Identification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoring
Genome Biology, 8
Hyun-Sook Kim, Hyun-Yi Kim, Su-Jung Kim, T. Kim, K. Lee, S. Baek, M. Ryu, B-H Nam, D. Zang (2013)Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis.
Annals of oncology : official journal of the European Society for Medical Oncology, 24 11
E. Borazanci, S. Millis, Jeff Kimbrough, N. Doll, D. Hoff, R. Ramanathan (2017)Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis.
Journal of gastrointestinal oncology, 8 1
v1.0, cancer incidence and mortality worldwide: IARC CancerBase No
D. Kanagavel, I. Pokataev, M. Fedyanin, A. Tryakin, I. Bazin, M. Narimanov, E. Yakovleva, A. Garin, S. Tjulandin (2010)A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology, 21 9
M. Maugeri-Saccà, L. Pizzuti, D. Sergi, M. Barba, F. Belli, S. Fattoruso, D. Giannarelli, A. Amodio, Sara Boggia, P. Vici, L. Lauro (2013)FOLFIRI as a second-line therapy in patients with docetaxel-pretreated gastric cancer: a historical cohort
Journal of Experimental & Clinical Cancer Research : CR, 32
C. Fuchs, J. Tomasek, Cho Yong, Filip Dumitru, R. Passalacqua, C. Goswami, H. Safran, L. Santos, G. Aprile, D. Ferry, B. Melichar, M. Tehfé, E. Topuzov, J. Zalcberg, I. Chau, W. Campbell, C. Sivanandan, J. Pikiel, M. Koshiji, Y. Hsu, A. Liepa, L. Gao, J. Schwartz, J. Tabernero (2014)Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
The Lancet, 383
Y. Bang, E. Cutsem, A. Feyereislova, H. Chung, L. Shen, A. Sawaki, F. Lordick, A. Ohtsu, Y. Omuro, T. Satoh, G. Aprile, E. Kulikov, Julie Hill, M. Lehle, J. Rüschoff, Yoon-Koo Kang (2010)Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
The Lancet, 376
R. Epelbaum, E. Shacham-Shmueli, B. Klein, A. Agbarya, B. Brenner, R. Brenner, E. Gez, T. Golan, A. Hubert, O. Purim, M. Temper, E. Tepper, A. Voss, K. Russell, A. Dvir, L. Soussan-Gutman, S. Stemmer, R. Geva (2015)Molecular Profiling-Selected Therapy for Treatment of Advanced Pancreaticobiliary Cancer: A Retrospective Multicenter Study
BioMed Research International, 2015
M. Kris, B. Johnson, L. Berry, D. Kwiatkowski, A. Iafrate, I. Wistuba, M. Varella-Garcia, W. Franklin, S. Aronson, P. Su, Y. Shyr, D. Camidge, L. Sequist, B. Glisson, F. Khuri, E. Garon, W. Pao, C. Rudin, J. Schiller, E. Haura, M. Socinski, K. Shirai, Heidi Chen, G. Giaccone, M. Ladanyi, K. Kugler, J. Minna, P. Bunn (2014)Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs.
JAMA, 311 19
E. Pectasides, M. Stachler, S. Derks, Yang Liu, S. Maron, Mirazul Islam, L. Alpert, H. Kwak, H. Kindler, B. Polite, M. Sharma, Kenisha Allen, Emily O’Day, S. Lomnicki, M. Maranto, R. Kanteti, Carrie Fitzpatrick, C. Weber, N. Setia, S. Xiao, J. Hart, R. Nagy, Kyoung-Mee Kim, M. Choi, B. Min, K. Nason, L. O'Keefe, Masayuki Watanabe, H. Baba, R. Lanman, A. Agoston, David Oh, Andrew Dunford, A. Thorner, M. Ducar, Bruce Wollison, Haley Coleman, Yuan Ji, M. Posner, K. Roggin, K. Turaga, Paul Chang, Kyle Hogarth, U. Siddiqui, A. Gelrud, G. Ha, S. Freeman, J. Rhoades, S. Reed, G. Gydush, D. Rotem, J. Davison, Y. Imamura, V. Adalsteinsson, Jeeyun Lee, A. Bass, D. Catenacci (2018)Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma.
Cancer discovery, 8 1
P Bohanes, DS Courvoisier, TV Perneger, P Morel, O Huber, AD Roth (2011)Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer
Swiss Med Wkly, 141
I. Kostopoulos, V. Karavasilis, M. Karina, Mattheos Bobos, N. Xiros, G. Pentheroudakis, G. Kafiri, P. Papakostas, E. Vrettou, G. Fountzilas (2009)Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy
BMC Cancer, 9
H. Wilke, K. Muro, E. Cutsem, S. Oh, G. Bodoky, Y. Shimada, S. Hironaka, N. Sugimoto, O. Lipatov, Tae-You Kim, D. Cunningham, P. Rougier, Y. Komatsu, J. Ajani, M. Emig, R. Carlesi, D. Ferry, K. Chandrawansa, J. Schwartz, A. Ohtsu (2014)Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial.
The Lancet. Oncology, 15 11
H. Park, S. Lim, Sora Kim, Sangwoo Kim, H. Kim, K. Kwack, Min Lee, Joo‐Hang Kim, Y. Moon (2016)Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution
PLoS ONE, 11
J. Ferlay, I. Soerjomataram, M. Ervik, R. Dikshit, S. Eser, C. Mathers (2013)GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer
Background Precision treatment of cancer uses biomarker-driven therapy to individualize and optimize patient care. Objective To evaluate real-life clinical experience with biomarker-driven therapy in metastatic gastric and esophageal cancer in Israel. Patients and Methods This multicenter retrospective cohort study included patients with metastatic gastric or esophageal cancer who were treated in the participating institutions and underwent biomarker-driven therapy. Treatment was considered to have a benefit if the ratio between the longest progression-free survival (PFS) post biomarker-driven therapy and the last PFS before the biomarker-driven therapy was ≥1.3. The null hypothesis was that ≤15% of patients gain such benefit. Results The analysis included 46 patients (61% men; median age, 58 years; 57% with poorly-differentiated tumors). At least one actionable (i.e., predictive of response to a specific therapy) biomarker was identified for each patient. Immunohistochemistry was performed on all samples and identified 1–8 (median: 3) biomarkers per patient (most commonly: low TS, high TOPO1, high TOP2A). Twenty-eight patients received therapy after the biomarker analysis (1–4 lines). In the 1st line after biomarker analysis, five patients (18%) achieved a partial response and five (18%) stable disease; the median (range) PFS was 129 (12–1155) days. Twenty-four patients were evaluable for PFS ratio analysis;
Targeted Oncology – Springer Journals
Published: Jan 20, 2018
Access the full text.
Sign up today, get DeepDyve free for 14 days.